Genelux (GNLX) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Genelux (GNLX) over the past year, gaining 62.4% versus a loss of 47.4%. Genelux is the larger company by market cap ($113.1 million vs $111.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | RANI |
|---|---|---|
| Share price | $2.50 | $0.792 |
| Market cap | $113.11M | $111.29M |
| 1-day change | -0.79% | -2.48% |
| YTD return | -42.66% | -39.84% |
| 1-year return | -47.37% | +62.42% |
| 5-year return | — | -95.88% |
| EPS (TTM) | $-0.86 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $3.87 |
| 52-week low | $2.29 | $0.445 |
| Distance from 52-week high | -70.71% | -79.53% |
| Average volume | 274.06K | 746.05K |
| Shares outstanding | 45.25M | 115.42M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed GNLX by 109.8 percentage points over the past year.
GNLX vs RANI FAQ
Which is bigger, Genelux or Rani Therapeutics?
Genelux (GNLX) is larger, with a market capitalization of $113.11M compared with $111.29M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, GNLX or RANI?
RANI returned +62.42% over the past 12 months, compared with -47.37% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.